A preclinical assessment of afatinib-treated HER2(+) gastric malignancies using Zr-89 trastuzumab

被引：0
|
作者：
Viola-Villegas, Nerissa [1 ]
Janjigian, Yelena [2 ]
Gomes-DaGama, Erica [2 ]
Holland, Jason [1 ]
de Stanchina, Elisa [3 ]
Lewis, Jason [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Radiol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Med, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Antitumor Assessment Core Facil, New York, NY 10021 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1105
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Zr-89 labeled trastuzumab as an effective non-invasive diagnostic agent for delineating Her2/neu-positive gastric cancer
    Viola-Villegas, Nerissa
    Janjigian, Yelena Y.
    Holland, Jason P.
    Divilov, Vadim
    Lewis, Jason S.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 : S358 - S358
  • [2] Positron emission tomography (PET) with 89Zr-labeled trastuzumab (89Zr-trastuzumab): Monitoring HER2 expression in HER2-positive gastric cancer in vivo
    Janjigian, Y. Y.
    Villegas, N. T.
    Holland, J. P.
    Shah, M. A.
    Divilov, V.
    Kelsen, D. P.
    Lewis, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] Characterization of 89Zr-trastuzumab for clinical HER2 immunoPET imaging
    Dijkers, E.
    Lub-de Hooge, M. N.
    Kosterink, J. G.
    Jager, P. L.
    Brouwers, A. H.
    Perk, L. R.
    van Dongen, G. A.
    de Vries, E. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] HER2 STATUS IN ADVANCED GASTRIC CARCINOMA PATIENTS TREATED WITH TRASTUZUMAB
    Gomez-Martin, C.
    Plaza, J. C.
    Del Valle, E.
    Pons Valladares, F.
    Jimenez Fonseca, P.
    Salud, A.
    Leon, A.
    Rivera, F.
    Garralda, E.
    Lopez-Rios, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 233 - 234
  • [5] Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
    Janjigian, Yelena Y.
    Viola-Villegas, Nerissa
    Holland, Jason P.
    Divilov, Vadim
    Carlin, Sean D.
    Gomes-DaGama, Erica M.
    Chiosis, Gabriela
    Carbonetti, Gregory
    de Stanchina, Elisa
    Lewis, Jason S.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (06) : 936 - 943
  • [6] Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study
    Lumish, Melissa A.
    Maron, Steven B.
    Paroder, Viktoriya
    Chou, Joanne F.
    Capanu, Marinela
    Philemond, Steven
    O'Donoghue, Joseph A.
    Schoder, Heiko
    Lewis, Jason S.
    Lyashchenko, Serge K.
    Pandit-Taskar, Neeta
    Janjigian, Yelena Y.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (05) : 724 - 730
  • [7] Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab
    Wakatsuki, Takeru
    Ishizuka, Naoki
    Hironaka, Shuichi
    Minashi, Keiko
    Kadowaki, Shigenori
    Goto, Masahiro
    Shoji, Hirokazu
    Hirano, Hidekazu
    Nakayama, Izuma
    Osumi, Hiroki
    Ogura, Mariko
    Chin, Keisho
    Yamaguchi, Kensei
    Takahari, Daisuke
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (06) : 801 - 812
  • [8] [64Cu]Cu-NOTA-Trastuzumab and [89Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression
    Simo, Cristina
    Shmuel, Shayla
    Vanover, Alex
    Pereira, Patricia M. R.
    MOLECULAR PHARMACEUTICS, 2024, 21 (12) : 6311 - 6322
  • [9] Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
    Dijkers, Eli C. F.
    Kosterink, Jos G. W.
    Rademaker, Anna P.
    Perk, Lars R.
    van Dongen, Guus A. M. S.
    Bart, Joost
    de Jong, Johan R.
    de Vries, Elisabeth G. E.
    Lub-de Hooge, Marjolijn N.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (06) : 974 - 981
  • [10] ANALYSIS OF USING TRASTUZUMAB FOR THE TREATMENT OF ADVANCED GASTRIC CANCER WITH HER2 POSITIVE
    Lechuga, D.
    Gay, J. G.
    Alva, M.
    Sanchez-Kobayashi, R.
    VALUE IN HEALTH, 2012, 15 (04) : A211 - A211
12345